Emyria Ltd (ASX:EMD)'s Michael Winlo speaks to Proactive soon after entering into an exclusive agreement with the University of Western Australia to examine and expand a unique library of proprietary, MDMA-like compounds which have been developed over the last 10 years. The agreement provides Emyria with a unique drug discovery pipeline, which will assist the company in becoming a leader in the development of psychedelic-assisted therapies and treatments for major neurological disorders.
Emyria gains exclusive access to drug discovery pipeline of novel psychedelic therapies
